KẾT QUẢ ĐIỀU TRỊ UNG THƯ TUYẾN TIỀN LIỆT DI CĂN BẰNG LIỆU PHÁP ỨC CHẾ ADROGEN

Abstract

Objective: Evaluation of the treatment results of metastatic prostate cancer with androgen deprivation therapy. Patients and methods: Retrospective cross-sectional study of 40 patients diagnosed with metastatic prostate cancer treated with Androgen inhibition therapy at Nghe An Oncology Hospital from January 1, 2018 to January 1, 2023. Results: Clinical characteristics at the time of diagnosis: bone pain (66.1%), insomnia (62.5%), dysuria (39.3%), 83.9% of patients had PSA levels >100ng/mL, bone metastasis (94.6%), lymph node metastasis (64.3%), patients with surgical orchiectomy (46.4%), patients with medical orchiectomy (53.6%). PSA levels were lowest after 3 months. Median progression-free survival (PFS) was 24.8±1.9 months, PFS in the surgical orchiectomy group was 20.8±1.5 months, PFS in the medical orchiectomy group was 29.8±3.3 months, the difference was not statistically significant. Conclusion: Androgen deprivation therapy is a fundamental, consistent and effective treatment in metastatic prostate cancer.